AAV: An Overview of Unanswered Questions.
AAV has been studied for 55 years and has been developed as a vector for about 35 years. By now, there is a fairly good idea of the dimensions of what would be useful to know to employ AAV optimally as a vector, but there are still many unanswered questions within the system. As with all biological systems, each good experiment raises further questions to answer. This article provides an overview of those areas in which unknown information can be identified and of those questions that have not yet been recognized. Some of these are touched on in the six review articles in this issue of Human Gene Therapy.
Guest Co-Editors, Department of Molecular Genetics and Microbiology, University of Florida College of Medicine , Gainesville, Florida.
Kenneth I
KI
Berns
Guest Co-Editors, Department of Molecular Genetics and Microbiology, University of Florida College of Medicine , Gainesville, Florida.
Nicholas
N
Muzyczka
D000229:Dependovirus / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans
AAV cell interactions; AAV immunity; AAV persistence; AAV toxicity